Abstract:Background Developing novel pharmaceuticals demands substantial investment despite high uncertainty of success and ultimate market value. While many established drug companies are highly profitable and have large portfolios of diversified assets, much of new drug innovation, a very high-risk, high-reward gambit, stems from smaller companies striving to bring their first products to market. While drug costs, and thus pharmaceutical company profits, can be controversial, it is unquestionable that the products from these companies provide great benefit to humanity. Hence, the ongoing success of the industry as a whole is quite relevant from a public health perspective. Methodology We sought to investigate factors influencing pharmaceutical company success using company stock performance on major US indices as a surrogate. As the profitability of large-capitalization (cap) pharmaceutical companies is well established, we focused on small- and mid-cap companies in this analysis. Small- and mid-cap pharmaceutical companies (both currently active and now defunct) and historical share prices were captured, including company details and the nature of drug pipelines. Funding by US academia was acquired via CMS.gov Open Payments and categorized into contributions < or ≥$100,000. Stock performance was considered good (+ ≥25%), mediocre (±25%), or poor (- ≥25%). Univariate and multivariate associations were assessed. Results Of the 420 companies included in the analysis, 101 (24%) had good, 76 (18%) mediocre, and 243 (58%) poor performance. The following were associated with performance in univariate analysis: initial public offering (IPO) price (P < 0.001), time from IPO (P < 0.001), number of drug programs (P = 0.019), and academic funding (P = 0.00013), with trend for diverse pipelines (both oncology and nononcology programs under development) (P = 0.069). On multivariate analysis, IPO price was inversely associated (P < 0.0001), while academic funding (P < 0.0001) and more drug programs (P = 0.0025) were positively associated with performance. Analysis of pharmaceutical IPOs since 2000 suggests a 20% rate of outright company failure. Conclusions The majority of included companies had lackluster stock performance, suggestive of low potential for drug development success and high probability of financial disaster. Robust drug pipelines and academic collaboration seem to be strongly related to company success.

Market reactions to capital increases: Insights from asset revaluation in pharmaceutical companies on the stock exchange

The Combined Effects of Financial and Market Indicators on the Valuation of New Listings: Evidence from the Biopharmaceutical Sector

Investigating the value level of pharmaceutical companies in Tehran Stock Exchange

Comparative Evaluation of Earnings Management and the Cost of Capital in Tehran Stock Exchange (Case Study: The Pharmaceutical Industry, Petrochemical and Cement)

Identification and Ranking of Financial, Non-Financial, and Behavioral Components Influencing Earnings Response Coefficient in the Iranian Capital Market (Data Mining Approach)

Investigating Changes in the Value of Corporate Fixed Assets as a Foreign Factor Affecting Reporting Quality, Financing, and Investment

Capital Structure Adjustment Speed and Expected Returns: Examination of Information Asymmetry as a Moderating Role

How does news affect biopharma stock prices?: An event study

Capital Structure Impact on Firm Performance: An Empirical Study of the Pharmaceutical Sector in India

Impact of Profitability, Capital Structure, and Firm Size on Pharmaceutical Company Valuation: Evidence from Indonesia

A Comparison of Working Capital Management of Chemical and Medicine Listed Companies in Tehran Stock Exchange

Investigating the Influence of Intellectual Capital on Organizational Performance with Organizational Learning Mediating

New drugs and stock market: how to predict pharma market reaction to clinical trial announcements

Corporate social responsibility and financial accounting concepts: evidence from an emerging market

Factors Related to Small- and Mid-Capitalization Pharmaceutical Company Success Using Stock Performance as a Surrogate

The reaction of sponsor stock prices to clinical trial outcomes: An event study analysis

A Quantitative Measure for Financial Resilience of Firms: Evidence from Tehran Stock Exchange

The Dynamic Impact of Oil Price on Investor Sentiment in Tehran Stock Exchange: An Industry-Level Analysis

The Impact of Current Ratio, Total Asset Turnover, Debt-Equity Ratio, Return on Equity, And Price Earning Ratio Toward Stock Return

Financial Market Reaction To R&D Volatility In The Pharmaceutical Industry. A Multi-Country Study

The Influence of Capital Structure and Profitability on Firm Value in The Pharmaceutical Sub-Sector for The Period 2017-2021